CASE REPORT

MIS-C and co-infection with *P. vivax* and *P. falciparum* in a child: a clinical conundrum

Michela Scalisi¹, Salvatore Giordano¹, Laura Antonella Canduscio¹, Maria Concetta Failla¹, Luca Messina¹, Elisa Sferrazza¹, Raffaella Rubino², Lucia Siracusa¹, Veronica Vanella¹, Antonio Cascio² and Claudia Colomba¹,²*

Abstract

**Background:** The ongoing Coronavirus Disease 2019 (COVID-19) epidemic represents an unprecedented global health challenge. Many COVID-19 symptoms are similar to symptoms that can occur in other infections. Malaria should always be considered in patients with SARS-CoV-2 infection returning from endemic areas.

**Case presentation:** We present the first case of multisystem inflammatory syndrome (MIS-C) and Plasmodium vivax-falciparum and SARS-CoV2 coinfection in children. Despite clearance of parasitaemia and a negative COVID-19 nasopharyngeal PCR, the patient’s clinical conditions worsened. The World Health Organization (WHO) criteria were used to make the diagnosis of MIS-C. Treatment with intravenous immunoglobulins and methylprednisolone was effective.

**Conclusions:** This case emphasizes the importance of considering malaria diagnosis in patients returning from endemic areas, even in the COVID-19 era. Malaria and SARS-CoV2 co-infection may increase the risk of MIS-C, for which early detection is critical for proper management.

**Keywords:** Case report, Multisystem inflammatory syndrome, SARS CoV2, Malaria, COVID-19

Background

The ongoing Coronavirus Disease 2019 (COVID-19) epidemic represents an unprecedented global health challenge. Currently, health systems around the world are enduring unparalleled efforts, and physicians continue to play a critical role in early detection and clinical management of COVID-19 pandemic [1]. Many COVID-19 symptoms, such as fever, myalgia, and headache, are similar to symptoms that can occur in other infections and an appropriate epidemiological approach and differential diagnosis are critical for selecting the appropriate clinical intervention [2, 3]. Despite the fact that the spread of COVID-19 in Africa has been slower than in other areas, 3 million cases and over 78,000 deaths due to COVID-19 have been recorded. Furthermore, African countries account for roughly 94% of all malaria cases and deaths worldwide. Malaria should always be considered in patients with SARS-CoV-2 infection returning from endemic regions due to overlapping geographical pathogens causing the COVID-19 and malaria co-infections and because the two clinical conditions resemble each other [4, 5]. However, there is a significant knowledge gap regarding the coexistence of these two diseases, particularly in children [6, 7].

We present the first case of *falciparum* and *vivax* malaria, as well as concurrent SARS-CoV-2 infection in an 8-year-old girl from Ivory Coast with the multisystem inflammatory syndrome in children (MIS-C). The case reminds us how important it is considering the patient’s history, travel history, and epidemiologic context even during this coronavirus pandemic.
Case presentation

An Italian 8-year-old girl from Ivory Coast presented to our hospital’s emergency department with a three-day fever, inappetence, and abdominal pain. Her previous medical history revealed risperidone-treated autism; she had no prior contact with a COVID-19-confirmed case. Her parents had received COVID 19 vaccination, but because her clinical picture was compatible with COVID-19, she was admitted to our department for a nasal swab for SARS-CoV2.

Due to the patient’s autistic condition, our physical examination was made more difficult; as far as we could tell, the child was conscious but in poor clinical conditions. Mild signs of dehydration and bilateral eyelid oedema, pharyngeal hyperaemia, and posterior cervical lymph node hypotrophy were noted. A respiratory examination revealed rhonchi. An abdominal examination showed mild hepatomegaly. The cardiovascular and neurological examination were both normal.

The laboratory workup revealed elevated inflammatory parameters (C-reactive protein, CRP 8.4 mg/dL, procalcitonin 2.2 μg/L, ferritin 1070 μg/L, bilirubin (total bilirubin 2.19 mg/dL, indirect bilirubin 1.2 mg/dL), lactate dehydrogenase (LDH) 716 U/L and transaminases (alanine transaminase, ALT 89 U/L and aspartate transaminase, AST 100 U/L). Her total blood count showed a low platelet count 4390/uL. A nasopharyngeal swab was positive for SARS-CoV2 polymerase chain reaction (PCR) as antibody IgG against SARS-CoV2.

Broad-spectrum antibiotic therapy was initiated with endovenous ceftriaxone.

During a detailed history in our infectious disease department, the mother reported that she was taking mefloquine hydrochloride for malaria prophylaxis for a recent trip to Africa with her daughter.

Therefore, thick and thin blood smear, rapid antigen test, and PCR for malaria were performed urgently, and the girl was diagnosed with malaria by Plasmodium falciparum and Plasmodium vivax with a parasitaemia of 5% (Fig. 1). After ruling out glucose 6 phosphate dehydrogenase deficiency, specific drug treatment with atovaquone-proguanil for a total of 3 days, followed by 14 days of primaquine, was started.

Despite repeated malaria smear after 5 days from initial presentation revealed clearance of parasitaemia and a COVID-19 nasopharyngeal PCR repeated 7 days after admission was confirmed as negative, the patient’s clinical conditions worsened. Fever was persistent as did the abdominal pain and a diffuse erythematosus rash appeared. Coinfections with Neisseria meningitidis, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus agalactiae, Klebsiella pneumoniae, Listeria monocytogenes, Escherichia coli were ruled out.

Further laboratory investigations were performed to document organ damage in accordance with guideline diagnostic criteria in cases where MIS-C was suspected. Cardiovascular involvement was investigated by analysis of troponin and pro B-type natriuretic peptide (ProBNP) values, respectively 8.3 ng/L and 520 pg/mL. Therefore, electrocardiogram, which was normal, and cardiac ultrasound, which showed mild mitral insufficiency, were performed. A chest X-ray (Fig. 2) showed accentuation of micronodular reticular pulmonary character pattern; ultrasound of the abdomen revealed hepatomegaly with starry sky appearance, as well as peritoneal fluid (Fig. 3).

The World Health Organization (WHO) criteria were used to make the diagnosis of MIS-C [7]. Therapy with a single dose of intravenous immunoglobulins (IVIG) at a dosage of 2g/Kg and intravenous methylprednisolone at a dosage of 30 mg/Kg/day was started in accordance with guidelines, and performed for three days, followed by methylprednisolone at a dosage of 2 mg/Kg/day.

Acute anaemia was treated with a blood transfusion. The treatment was well tolerated and quickly effective, resulting in an overall improvement in the patient’s clinical conditions. The child became apyretic after administration of immunoglobulin and the first bolus of methylprednisolone. Blood tests gradually returned to normal (Table 1).
Discussion
This is the first report of MIS-C and *Plasmodium vivax* and *falciparum* malaria co-infection. By presenting this case, we aimed to draw attention to a rare travel related infection masked by a pandemic infection. Indeed, since the end of 2019, the global outbreak of COVID-19 has spread rapidly posing a major challenge to many health care systems around the world [8]. In this situation, co-infections present a unique challenge to clinicians and it is essential to remember that neither co-infection with other pathogens can be ruled out when COVID-19 is confirmed, nor does a positive test for other pathogens completely negate the presence of co-infection with COVID-19.

This is especially true in malaria-endemic areas or among people who have recently returned from malaria-endemic countries. Malaria and COVID-19 can actually present with fever, myalgia, fatigue, headache, gastrointestinal symptoms, and both can have a negative impact on the course of the other [9, 10]. Furthermore, the diagnosis of malaria is already elusive in a non-endemic country; this difficulty appears to be exacerbated by overlap of symptoms and signs with COVID-19. The similarity in the non-specific symptoms and febrile illness associated with COVID-19 and malaria makes missing a malaria diagnosis in the COVID-19 pandemic highly likely especially in countries not endemic for malaria.

In our case, the patient was admitted due to COVID-19 and was found to have a concomitant *falciparum* and *vivax* malaria infection whose pattern of over-expressed cytokines overlaps with that of COVID-19. Malaria with severe manifestations may cause an elevated pro-inflammatory response (IL 6, IL 1, and tumor necrosis factor alpha increase during haemolysis from malarial infection). Therefore, coinfection with malaria and SARS-CoV2 may lead to an increased risk of developing MIS-C in pediatric age. Co-infection with a parasite and a virus, in particular, can place a double burden on the body’s immune system. Immune cells may undergo a dilemma of whether to produce a response to eliminate one pathogen or the other and ultimately end up with an exaggerated immune response. MIS-C is a novel dangerous and potentially life-threatening entity associated with a wide range of clinical features including persistent fever, digestive symptoms, rash, bilateral non purulent conjunctivitis, mucocutaneous inflammation signs, and frequent cardiovascular involvement. MIS-C is frequently associated with hemodynamic failure, with acute cardiac dysfunction requiring hemodynamic

![Fig. 2](image1.png) Chest X-ray. Hypo transparency of the right lung fields with accentuation of micronodular reticular pulmonary character pattern, especially on the right side

![Fig. 3](image2.png) Abdomen ultrasound. Hepatomegaly with starry sky appearance, pelvic intraperitoneal fluid
support in 60 to 75% of cases, sometimes leading to death [11]. We diagnosed our patient with MIS-C due to clinical deterioration characterized by continuous fever, a multisystem organ involvement with elevation of inflammatory markers, despite the clearance of parasitaemia after malaria treatment. Many altered biochemical parameters such as anaemia, thrombocytopenia, elevated bilirubin, CRP, procalcitonin, AST, ALT, ferritin, GGT, IL 6, and reduced sodium and albumin levels can be related to both malaria and MIS-C therefore require proper interpretation (Table 2). In severe malaria, there is generally a decline in red blood cell, haemoglobin, and platelet counts due to sequestration of infected red blood cells caused by the activation of endothelial activation markers and surface adhesion molecules. However, ours was not a case of severe malaria, but rather a case of malaria complicated by MIS-C in fact even SARS-CoV-2 infection is associated with a cytokine cascade and endothelial activation [12–14].

MIS-C management has evolved over the course of the pandemic. Current guidelines recommend IVIG and/or corticosteroids as first-line therapy. Other interventions are determined by the disease severity, outcome, and response

| Laboratory Tests          | 1th day | 3rd day | 6th day | Reference Range         |
|---------------------------|---------|---------|---------|-------------------------|
| White blood cell count    | 7.430   | 12.240  | 12.610  | 5.4–9.7 10³/uL          |
| Absolute neutrophil count | 5.430   | 6.170   | 6.680   | 2.6–6 10³/uL            |
| Lymphocytes               | 1.55    | 3.980   | 5.170   | 1.2–2.8 10³/uL          |
| Haemoglobin               | 11.2    | 8.3     | 9       | 11.3–13.4 g/dL          |
| Platelets                 | 43,900  | 27,400  | 130,600 | 219–339 10³/uL          |
| CRP                       | 8.4     | 14.34   | 3       | 0–0.5 mg/dL             |
| Procalcitonin             | 2.2     | 7.26    | 1.4     | 0.02–0.05 μg/L          |
| Total Bilirubin           | 2.19    | 4.01    | 1.29    | 0–1 mg/dL               |
| Bilirubin Direct          | 0.98    | 3.31    | 1.15    | 0–0.29                  |
| Indirect Bilirubin        | 1.20    | 0.7     | 0.14    | 0–0.90                  |
| Sodimia                   | 137     | 132     | 137     | 138–145 mmol/L          |
| Albumin                   | 3.7     | 2.8     | 3       | 3.8–5.4 g/dL            |
| AST                       | 100     | 76      | 47      | 15–55 U/L               |
| ALT                       | 89      | 62      | 46      | 5–33 U/L                |
| Gamma-glutamyl-transpeptidasi (gGT) |         |         |         |                        |
| LDH                       | 716     | 718     | 619     | 135–214 U/L             |
| Cholesterol               | 83      | 67      |         | 110–200 mg/dL           |
| Triglycerides             | 296     | 476     | 445     | 35–114 mg/dL            |
| Ferritin                  | 1070    | 1846    |         | 10–140 μg/L             |
| Interleukin 6 (IL6)       | 588     | 332     |         | 0–7 pg/mL               |
| ProBNP                    | 141     | 520     |         | 0–145 pg/mL             |
| Troponin                  | 5       | 8.3     |         | 0–14 ng/L               |

| Laboratory changes in patient with malaria and MIS-C |
|------------------------------------------------------|
| **MALARIA** | **MIS-C** |
| Anaemia     | X          | X        |
| Thrombocytopenia | X        | X        |
| Leukopenia or leukocytosis | X        | X Leukocytosis with neutrophilia and lymphopenia |
| Increased CRP                  | X        | X        |
| Procalcitonin          | X        | X        |
| Increased fibrinogen   | X        | X        |
| Increased D-dimer     | X        | X        |
| Increased LDH         | X        | X        |
| Hypertransaminasemia  | X        | X        |
| Hyperbilirubinemia    | indirect | direct   |
| Hyponatremia          | X        | X        |
| Increased IL-6        | X        | X        |
| Hypoglycemia          | X        | X        |
| Hyperferritinemia     | X        | X        |
| Metabolic acidosis    | X        | X        |
| Hypoalbuminemia       | X        | X        |
| Increased cardiac enzymes | X        | X        |
to initial therapy. Antithrombotic therapy and second-line treatment with several immunomodulatory drugs (interleukin-1 inhibitor, interleukin-6 inhibitor), and other supportive therapeutic agents are used concurrently in these cases [15].

Single case reports of patients with malaria and COVID-19 co-infection have been described by several authors [16–18] and a recent systematic review reports concomitant infections of SARS-CoV-2 and malaria, mainly in adults (age range 4–67 years) [6]. There are very few cases of co-infection malaria-COVID described in the child. Adetola et al. described four children with COVID and malaria treated with a full course of anti-malaria medications [19]. Rashmi Kishore et al. reported one case of *P. vivax* malaria reactivation in an Indian 10-year-old boy suggesting a possible role of COVID-19 in inducing malarial relapse [20]. Although the exact mechanism causing this activation is unknown, the cytokine cascade associated with systemic disease could also induce reactivation of *Plasmodium vivax* from a previous infection with dormant liver stage parasites or hypnozoites. In our case we can't say if it was the first malaria vivax infection or a case of malarial relapse because we don't know if it was her first trip to Africa since she was born in Italy.

In none of the few cases of co-infection described to date COVID-19 has manifested itself in a severe form and required intensive support [21].

Ours is the first severe form of COVID-19 and malaria co-infection in the child due to the establishment of MIS-C. Regarding malaria treatment, the role of anti-malarials, e.g. artemisinin derivates and chloroquine, in the COVID-19 pandemic is complex. Artemisinin derivates, artemisinin-based combination therapy, and chloroquine have all been shown in vitro to be effective against SARS-CoV-2 [22, 23]. Several clinical trials, however, failed to confirm such a beneficial effect [24, 25].

**Conclusions**

This case highlights how important is to consider the patient's travel history, the epidemiologic setting and alternative diagnoses even under pandemic conditions [26]. Malaria should always be considered in patients who have recently returned from endemic areas. COVID-19 and malaria co-infection can be dangerous because the combination causes a cytokine storm, which is responsible for the more severe COVID-19 manifestations in children [14, 27, 28], such as MIS-C. As paediatric infectious disease physicians, it is our responsibility to stress the importance of the diagnosis of MIS-C in all patients with SARS-CoV-2 infection despite the evidence of other etiological causes that could explain and confound the clinical case. Our case again demonstrates the importance of malaria prophylaxis. If the patient had received malaria prophylaxis during her trip, she probably would have been protected from malaria and would have had a less severe course of MIS-C.

**Abbreviations**

MIS-C: Multisystem Inflammatory Syndrome in Children; PCR: Polymerase Chain Reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19: Coronavirus Disease 2019; LDH: lactate dehydrogenase; CRP: C-reactive protein; IL 6: interleukin 6; AST: aspartate transaminase; ALT: alanine transaminase.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

MS, SG, LAC, MCF, UM, ES, LS, YV and CC all contributed to the patient’s clinical management, data collection and literature review. RR and CC revised the manuscript. CC and AC supervised and coordinated the work and revised the manuscript. All authors contributed to the final version of the paper. All authors read and approved the final manuscript.

**Funding**

There are no funding sources to declare.

**Availability of data and materials**

All data used and/or analysed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent for publication was obtained from parents.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Division of Paediatric Infectious Diseases, “G. Di Cristina” Hospital, ARNAS Civico, Palermo, Italy. 2 Department of Health Promotion, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.

**Received:** 7 April 2022  **Accepted:** 30 June 2022  **Published online:** 27 July 2022

**References**

1. Jochum J, Kreuels B, Tannich E, Huber S, Schulee Zur Wiesch J, Schmiedel S, et al. Malaria in the time of COVID-19: do not miss the real cause of illness. Trop Med Infect Dis. 2021;6(2):40.
2. Nghochuzie NN, Olwal CO, Udoakang A, Amenga-Etego L, Amambua-Ngwa A. Pausing the fight against malaria to combat the COVID-19 pandemic in Africa: is the future of malaria bleak? Front Microbiol. 2020. https://doi.org/10.3389/fmicb.2020.01476.
3. Siracusa L, Caccio A, Giordano S, Medaglia AA, Restivo GA, Pirrone I, et al. Neurological complications in paediatric patients with SARS-CoV-2 infection: a systematic review of the literature. Ital J Pediatr. 2021;47(1):123.
4. Coronavirus disease (COVID-19) [Internet]. [cited 2021 Nov 4]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
5. World malaria report 2020 [Internet]. [cited 2022 Jan 1]. Available from: https://www.who.int/publications/i/item/9789246015791.
6. Wilairatana P, Masangkay FR, Koteptu KKU, Milanez GDJ, Koteptu M. Prevalence and characteristics of malaria among COVID-19 individuals: a systematic review, meta-analysis, and analysis of case reports. PLoS Negl Trop Dis. 2021;15(10):e0009766.
7. GRUPPO DI LAVORO SU COVID-19 IN PEDIATRIA DELLA REGIONE EMILIA-ROMAGNA (RE-CO-PED)*. Gestione del Covid-19 in età pediatrica: documento di consenso. Medico e Bambino 2021; 40(2): 85–101.
8. Caglar B, Karaali R, Balkan II, Mete A, Aygun G. COVID-19 and Plasmodium ovale Malaria: a rare case of co-infection. Korean J Parasitol. 2021;59(4):395–402.
9. Di Gennaro F, Marotta C, Locantore P, Pizzol D, Puototo G. Malaria and COVID-19: Common and Different Findings. Trop Med Infect Dis. 5(3):141.

10. Hussein MIH, Albaishar AAD, Elawad OAMA, Homeida A. Malaria and COVID-19: unmasking their ties. Malar J. 2020;19(1):457.

11. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–88.

12. Akhmola S, Indari O, Kashyap D, Varshney N, Rani A, Sonkar C, et al. Recent updates on COVID-19: a holistic review. Helvyon. 2020;6(12):e05706.

13. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med. 2020;9(5):1417.

14. Amaoa LE, Donu D, Abuaku B, Ahorlu C, Arhinful D, Afari E, et al. Probing the composition of Plasmodium species contained in malaria infections in the Eastern region of Ghana. BMC Public Health. 2019;19(1):1617.

15. Mahmoud S, El-Kalliny M, Kobyty A, El-Ganzoury M, Fouda E, Ibrahim H. Treatment of MIS-C in Children and Adolescents. Curr Pediatr Rep. 2022. https://doi.org/10.1007/s40124-021-00259-4.

16. Correia MJ, Frade L, Guerreiro R, Araujo I, Baptista T, Forseca C, et al. A Patient with Severe Malaria and COVID-19: How Do You Tell the Difference between These Infections? EJCRIM. 2020;7. https://doi.org/10.12890/2020_002007.

17. Ray M, Vazifdar A, Shiva Prakash S. Co-infection with Malaria and Coronavirus Disease-2019. J Glob Infect Dis. 2020;12(3):162–3.

18. Shahid Z, Karim N, Shahid F, Yousaf Z. COVID-19 Associated Imported Plasmodium vivax Malaria Relapse: First Reported Case and Literature Review. Rep Rep Trop Med. 2021;2:77–80.

19. Sardar S, Sharma R, Alyamani TYM, Aboukarnar M. COVID-19 and Plasmodium vivax malaria co-infection. IDCases. 2020. https://doi.org/10.1016/j.idcr.2020.e00879.

20. Kishore R, Dhakad S, Arif N, Dar L, Mirdha BR, Aggarwal R, et al. COVID-19: Possible Cause of Induction of Relapse of Plasmodium vivax Infection. Indian J Pediatr. 2020;87(9):751–2.

21. Adetola HH, Ishola D, Molabt IMO, Bangura J, Sesay IM, Pearce R, et al. Clinical presentations and management of COVID-19 infected children seen in a district health facility in Kambia, northern Sierra Leone. Pan Afr Med J. 2020;37(Suppl 1):28.

22. Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, et al. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect Dis. 2020;6(9):2524–31.

23. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Kiasek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.

24. Boulineau DR, Pullen MF, Bangdivala AS, Pasticik KA, Lofgren SM, Okabor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517–25.

25. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; doi: https://doi.org/10.1136/bmj.m1849.

26. Identifying and combating the impacts of COVID-19 on malaria | BMC Medicine | Full Text [Internet]. [cited 2021 Nov 3]. Available from: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01710-x.

27. White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011. https://doi.org/10.1186/1475-2875-10-297.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.